Show simple item record

dc.contributor.authorCanelo-Aybar, C
dc.contributor.authorFerreira, DS
dc.contributor.authorBallesteros, M
dc.contributor.authorPosso, M
dc.contributor.authorMontero, N
dc.contributor.authorSolà, I
dc.contributor.authorSaz-Parkinson, Z
dc.contributor.authorLerda, D
dc.contributor.authorRossi, PG
dc.contributor.authorDuffy, SW
dc.contributor.authorFollmann, M
dc.contributor.authorGräwingholt, A
dc.contributor.authorAlonso-Coello, P
dc.date.accessioned2021-03-22T18:25:21Z
dc.date.available2021-03-22T18:25:21Z
dc.date.issued2021-02-25
dc.identifier.citationCanelo-Aybar C, Ferreira DS, Ballesteros M, et al. Benefits and harms of breast cancer mammography screening for women at average risk of breast cancer: A systematic review for the European Commission Initiative on Breast Cancer. Journal of Medical Screening. February 2021. doi:10.1177/0969141321993866en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/70810
dc.description.abstractOBJECTIVES: Mammography screening is generally accepted in women aged 50-69, but the balance between benefits and harms remains controversial in other age groups. This study systematically reviews these effects to inform the European Breast Cancer Guidelines. METHODS: We searched PubMed, EMBASE and Cochrane Library for randomised clinical trials (RCTs) or systematic reviews of observational studies in the absence of RCTs comparing invitation to mammography screening to no invitation in women at average breast cancer (BC) risk. We extracted data for mortality, BC stage, mastectomy rate, chemotherapy provision, overdiagnosis and false-positive-related adverse effects. We performed a pooled analysis of relative risks, applying an inverse-variance random-effects model for three age groups (<50, 50-69 and 70-74). GRADE (Grading of Recommendations Assessment, Development and Evaluation) was used to assess the certainty of evidence. RESULTS: We identified 10 RCTs including 616,641 women aged 38-75. Mammography reduced BC mortality in women aged 50-69 (relative risk (RR) 0.77, 95%CI (confidence interval) 0.66-0.90, high certainty) and 70-74 (RR 0.77, 95%CI 0.54-1.09, high certainty), with smaller reductions in under 50s (RR 0.88, 95%CI 0.76-1.02, moderate certainty). Mammography reduced stage IIA+ in women 50-69 (RR 0.80, 95%CI 0.64-1.00, very low certainty) but resulted in an overdiagnosis probability of 23% (95%CI 18-27%) and 17% (95%CI 15-20%) in under 50s and 50-69, respectively (moderate certainty). Mammography was associated with 2.9% increased risk of invasive procedures with benign outcomes (low certainty). CONCLUSIONS: For women 50-69, high certainty evidence that mammography screening reduces BC mortality risk would support policymakers formulating strong recommendations. In other age groups, where the net balance of effects is less clear, conditional recommendations will be more likely, together with shared decision-making.en_US
dc.format.extent969141321993866 - ?
dc.languageeng
dc.publisherSageen_US
dc.relation.ispartofJournal of Medical Screening
dc.subjectGuidelinesen_US
dc.subjectbreast canceren_US
dc.subjectmammographyen_US
dc.subjectmass screeningen_US
dc.titleBenefits and harms of breast cancer mammography screening for women at average risk of breast cancer: A systematic review for the European Commission Initiative on Breast Cancer.en_US
dc.typeArticleen_US
dc.identifier.doi10.1177/0969141321993866
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/33632023en_US
pubs.notesNot knownen_US
pubs.publication-statusPublished onlineen_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record